ArticleBMC cancer2023

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.

Shane O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.